TY - BOOK PY - 2013 DA - 2013// TI - UNAIDS Report on the Global AIDS Epidemic PB - World Health Organization CY - Geneva ID - ref1 ER - TY - STD TI - National AIDS and STI Control Programme. Kenya AIDS Indicator Survey 2012: Preliminary Report. Nairobi: Ministry of Health; 2013. ID - ref2 ER - TY - BOOK PY - 2012 DA - 2012// TI - Kenya AIDS Epidemic Update PB - Ministry of Health CY - Nairobi ID - ref3 ER - TY - JOUR AU - Braitstein, P. AU - Ayuo, P. AU - Mwangi, A. AU - Wools-Kaloustian, K. AU - Musick, B. AU - Siika, A. PY - 2010 DA - 2010// TI - Sustainability of first-line antiretroviral regimens: findings from a large HIV treatment program in western Kenya JO - J Acquir Immune Defic Syndr VL - 53 UR - https://doi.org/10.1097/QAI.0b013e3181b8f26e DO - 10.1097/QAI.0b013e3181b8f26e ID - Braitstein2010 ER - TY - JOUR AU - Foreman, C. AU - Gazzard, B. AU - Johnson, M. AU - Sharott, P. AU - Collins, S. PY - 2012 DA - 2012// TI - Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers JO - Sex Transm Infect VL - 88 UR - https://doi.org/10.1136/sextrans-2011-050438 DO - 10.1136/sextrans-2011-050438 ID - Foreman2012 ER - TY - JOUR AU - Dong, B. J. AU - Zheng, Y. AU - Hughes, M. D. AU - Frymoyer, A. AU - Verotta, D. AU - Lizak, P. PY - 2012 DA - 2012// TI - Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women JO - AIDS VL - 26 UR - https://doi.org/10.1097/QAD.0b013e328351a521 DO - 10.1097/QAD.0b013e328351a521 ID - Dong2012 ER - TY - JOUR AU - Ngo-Giang-Huong, N. AU - Jourdain, G. AU - Amzal, B. AU - Sang-a-gad, P. AU - Lertkoonalak, R. AU - Eiamsirikit, N. PY - 2011 DA - 2011// TI - Resistance patterns selected by nevirapine vs efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a Bayesian analysis JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0027427 DO - 10.1371/journal.pone.0027427 ID - Ngo-Giang-Huong2011 ER - TY - JOUR AU - Darwich, L. AU - Esteve, A. AU - Ruiz, L. AU - Bellido, R. AU - Clotet, B. AU - Martinez-Picado, J. PY - 2008 DA - 2008// TI - Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption JO - Antivir Ther VL - 13 ID - Darwich2008 ER - TY - STD TI - Khienprasit N, Chaiwarith R, Sirisanthana T, Supparatpinyo K. Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther. 2011;8:42. ID - ref9 ER - TY - JOUR AU - Riska, P. AU - Lamson, M. AU - MacGregor, T. AU - Sabo, J. AU - Hattox, S. AU - Pav, J. PY - 1999 DA - 1999// TI - Disposition and biotransformation of the antiretroviral drug nevirapine in humans JO - Drug Metab Dispos VL - 27 ID - Riska1999 ER - TY - JOUR AU - Erickson, D. A. AU - Mather, G. AU - Trager, W. F. AU - Levy, R. H. AU - Keirns, J. J. PY - 1999 DA - 1999// TI - Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450 JO - Drug Metab Dispos VL - 27 ID - Erickson1999 ER - TY - JOUR AU - Klein, K. AU - Lang, T. AU - Saussele, T. AU - Barbosa-Sicard, E. AU - Schunck, W. H. AU - Eichelbaum, M. PY - 2005 DA - 2005// TI - Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz JO - Pharmacogenet Genomics VL - 15 UR - https://doi.org/10.1097/01213011-200512000-00004 DO - 10.1097/01213011-200512000-00004 ID - Klein2005 ER - TY - JOUR AU - Ngaimisi, E. AU - Mugusi, S. AU - Minzi, O. M. AU - Sasi, P. AU - Riedel, K. D. AU - Suda, A. PY - 2010 DA - 2010// TI - Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients JO - Clin Pharmacol Ther VL - 88 UR - https://doi.org/10.1038/clpt.2010.172 DO - 10.1038/clpt.2010.172 ID - Ngaimisi2010 ER - TY - JOUR AU - Habtewold, A. AU - Amogne, W. AU - Makonnen, E. AU - Yimer, G. AU - Riedel, K. D. AU - Ueda, N. PY - 2011 DA - 2011// TI - Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients JO - J Antimicrob Chemother VL - 66 UR - https://doi.org/10.1093/jac/dkr304 DO - 10.1093/jac/dkr304 ID - Habtewold2011 ER - TY - JOUR AU - Lang, T. AU - Klein, K. AU - Fischer, J. AU - Nüssler, A. K. AU - Neuhaus, P. AU - Hofmann, U. PY - 2001 DA - 2001// TI - Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver JO - Pharmacogenetics VL - 11 UR - https://doi.org/10.1097/00008571-200107000-00004 DO - 10.1097/00008571-200107000-00004 ID - Lang2001 ER - TY - JOUR AU - Haas, D. W. AU - Ribaudo, H. J. AU - Kim, R. B. AU - Tierney, C. AU - Wilkinson, G. R. AU - Gulick, R. M. PY - 2004 DA - 2004// TI - Pharmacogenetics of Efavirenz and central nervous system side effects: an adult AIDS clinical trials group study JO - AIDS VL - 18 ID - Haas2004 ER - TY - JOUR AU - Matimba, A. AU - Oluka, M. N. AU - Ebeshi, B. U. AU - Sayi, J. AU - Bolaji, O. O. AU - Guantai, A. N. PY - 2008 DA - 2008// TI - Establishment of a biobank and pharmacogenetics database of African populations JO - Eur J Hum Genet VL - 16 UR - https://doi.org/10.1038/ejhg.2008.49 DO - 10.1038/ejhg.2008.49 ID - Matimba2008 ER - TY - JOUR AU - Li, J. AU - Menard, V. AU - Benish, R. L. AU - Jurevic, R. J. AU - Guillemette, C. AU - Stoneking, M. PY - 2012 DA - 2012// TI - Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment JO - Pharmacogenomics VL - 13 UR - https://doi.org/10.2217/pgs.11.160 DO - 10.2217/pgs.11.160 ID - Li2012 ER - TY - JOUR AU - Mehlotra, R. K. AU - Bockarie, M. J. AU - Zimmerman, P. A. PY - 2007 DA - 2007// TI - CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment JO - Br J Clin Pharmacol VL - 64 UR - https://doi.org/10.1111/j.1365-2125.2007.02884.x DO - 10.1111/j.1365-2125.2007.02884.x ID - Mehlotra2007 ER - TY - JOUR AU - Dahri, K. AU - Ensom, M. H. PY - 2007 DA - 2007// TI - Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? JO - Clin Pharmacokinet VL - 46 UR - https://doi.org/10.2165/00003088-200746020-00002 DO - 10.2165/00003088-200746020-00002 ID - Dahri2007 ER - TY - JOUR AU - Duong, M. AU - Buisson, M. AU - Peytavin, G. AU - Kohli, E. AU - Piroth, L. AU - Martha, B. PY - 2005 DA - 2005// TI - Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors JO - Ann Pharmacother VL - 39 UR - https://doi.org/10.1345/aph.1E563 DO - 10.1345/aph.1E563 ID - Duong2005 ER - TY - JOUR AU - Haas, D. W. AU - Gebretsadik, T. AU - Mayo, G. AU - Menon, U. N. AU - Acosta, E. P. AU - Shintani, A. PY - 2009 DA - 2009// TI - Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans JO - J Infect Dis VL - 199 UR - https://doi.org/10.1086/597125 DO - 10.1086/597125 ID - Haas2009 ER - TY - JOUR AU - Gozalo, C. AU - Gérard, L. AU - Loiseau, P. AU - Morand-Joubert, L. AU - Peytavin, G. AU - Molina, J. M. PY - 2011 DA - 2011// TI - ANRS 081 Study Group. Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial JO - Basic Clin Pharmacol Toxicol VL - 109 UR - https://doi.org/10.1111/j.1742-7843.2011.00780.x DO - 10.1111/j.1742-7843.2011.00780.x ID - Gozalo2011 ER - TY - JOUR AU - Heil, S. G. AU - Ende, M. E. AU - Schenk, P. W. AU - Heiden, I. AU - Lindemans, J. AU - Burger, D. PY - 2012 DA - 2012// TI - Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals JO - Ther Drug Monit VL - 34 UR - https://doi.org/10.1097/FTD.0b013e31824868f3 DO - 10.1097/FTD.0b013e31824868f3 ID - Heil2012 ER - TY - JOUR AU - Mahungu, T. AU - Smith, C. AU - Turner, F. AU - Egan, D. AU - Youle, M. AU - Johnson, M. PY - 2009 DA - 2009// TI - Cytochrome P450 2B6 516G–>T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population JO - HIV Med VL - 10 UR - https://doi.org/10.1111/j.1468-1293.2008.00689.x DO - 10.1111/j.1468-1293.2008.00689.x ID - Mahungu2009 ER - TY - JOUR AU - Honda, M. AU - Muroi, Y. AU - Tamaki, Y. AU - Saigusa, D. AU - Suzuki, N. AU - Tomioka, Y. PY - 2011 DA - 2011// TI - Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether JO - Drug Metab Dispos VL - 39 UR - https://doi.org/10.1124/dmd.111.040352 DO - 10.1124/dmd.111.040352 ID - Honda2011 ER - TY - JOUR AU - Wyen, C. AU - Hendra, H. AU - Vogel, M. AU - Hoffmann, C. AU - Knechten, H. AU - Brockmeyer, N. H. PY - 2008 DA - 2008// TI - German Competence Network for HIV/AIDS. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients JO - J Antimicrob Chemother VL - 61 UR - https://doi.org/10.1093/jac/dkn029 DO - 10.1093/jac/dkn029 ID - Wyen2008 ER - TY - JOUR AU - Schipani, A. AU - Wyen, C. AU - Mahungu, T. AU - Hendra, H. AU - Egan, D. AU - Siccardi, M. PY - 2011 DA - 2011// TI - Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals JO - J Antimicrob Chemother VL - 66 UR - https://doi.org/10.1093/jac/dkr087 DO - 10.1093/jac/dkr087 ID - Schipani2011 ER - TY - JOUR AU - Haas, D. W. AU - Smeaton, L. M. AU - Shafer, R. W. AU - Robbins, G. K. AU - Morse, G. D. AU - Labbe, L. PY - 2005 DA - 2005// TI - Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an adult aids clinical trials group study JO - J Infect Dis VL - 192 UR - https://doi.org/10.1086/497610 DO - 10.1086/497610 ID - Haas2005 ER - TY - JOUR AU - Saitoh, A. AU - Sarles, E. AU - Capparelli, E. AU - Aweeka, F. AU - Kovacs, A. AU - Burchett, S. K. PY - 2007 DA - 2007// TI - CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children JO - AIDS VL - 21 UR - https://doi.org/10.1097/QAD.0b013e3282ef9695 DO - 10.1097/QAD.0b013e3282ef9695 ID - Saitoh2007 ER - TY - JOUR AU - Ngaimisi, E. AU - Habtewold, A. AU - Minzi, O. AU - Makonnen, E. AU - Mugusi, S. AU - Amogne, W. PY - 2013 DA - 2013// TI - Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0067946 DO - 10.1371/journal.pone.0067946 ID - Ngaimisi2013 ER - TY - JOUR AU - Haïm-Boukobza, S. AU - Morand-Joubert, L. AU - Flandre, P. AU - Valin, N. AU - Fourati, S. AU - Sayon, S. PY - 2011 DA - 2011// TI - Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml JO - AIDS VL - 25 UR - https://doi.org/10.1097/QAD.0b013e3283427de3 DO - 10.1097/QAD.0b013e3283427de3 ID - Haïm-Boukobza2011 ER - TY - JOUR AU - Graham, S. M. AU - Masese, L. AU - Gitau, R. AU - Jalalian-Lechak, Z. AU - Richardson, B. A. AU - Peshu, N. PY - 2010 DA - 2010// TI - Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment JO - J Infec Dis VL - 202 UR - https://doi.org/10.1086/656790 DO - 10.1086/656790 ID - Graham2010 ER - TY - JOUR AU - Graham, S. M. AU - Jalalian-Lechak, Z. AU - Shafi, J. AU - Chohan, V. AU - Deya, R. W. AU - Jaoko, W. PY - 2012 DA - 2012// TI - Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA JO - J Acquir Immune Defic Syndr VL - 60 UR - https://doi.org/10.1097/QAI.0b013e31825bd703 DO - 10.1097/QAI.0b013e31825bd703 ID - Graham2012 ER - TY - STD TI - National AIDS and STI Control Programme. Guidelines for Antiretroviral Therapy in Kenya. 3rd ed. Nairobi: Ministry of Health; 2005. ID - ref35 ER - TY - JOUR AU - Oyugi, J. H. AU - Byakika-Tusiime, J. AU - Charlebois, E. D. AU - Kityo, C. AU - Mugerwa, R. AU - Mugyenyi, P. PY - 2004 DA - 2004// TI - Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting JO - J Acquir Immune Defic Syndr VL - 36 UR - https://doi.org/10.1097/00126334-200408150-00014 DO - 10.1097/00126334-200408150-00014 ID - Oyugi2004 ER - TY - JOUR AU - Veldkamp, A. I. AU - Heeswijk, R. P. AU - Mulder, J. W. AU - Meenhorst, P. L. AU - Hoetelmans, R. M. AU - Lange, J. M. PY - 2001 DA - 2001// TI - Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 non-nucleoside reverse transcriptase inhibitor nevirapine JO - Ther Drug Monit VL - 23 UR - https://doi.org/10.1097/00007691-200112000-00002 DO - 10.1097/00007691-200112000-00002 ID - Veldkamp2001 ER - TY - JOUR AU - Minzi, O. M. S. AU - Ngaimisi, E. PY - 2010 DA - 2010// TI - Bioanalytical method for determination of nevirapine in-vivo in resource constrained laboratories JO - J Chem Pharm Res VL - 2 ID - Minzi2010 ER -